According to the most recent treatment guidelines, GLP-1 agonists may be most appropriate for people with type 2 diabetes who are at a high risk for heart disease or who already have heart disease
The most recent consensus algorithm released by the ADA/EASD lists GLP-1 analogues as a treatment option for consideration as a Tier 2 agent, or less well-validated therapy, in T2DM patients ( FIGURE 1 )
It may be considered for some patients with a BMI of 2729.9 and certain weight-related conditions, but final eligibility must be determined by a licensed provider
In 2021, FDA approved Novos Wegovy for chronic weight management
Around this point, many people begin to notice the medications full appetite-suppressing effects
Therefore, this review presents the triangle relationship of obesity, DM as well as cancer development and elucidates the treatment of overweight-associated T2DM with semaglutide, focusing on the question of whether the development of these conditions can be combated or if any severe side effects should be considered of this therapy
